Published in Coron Artery Dis on June 01, 2002
Aortic valve calcification in 499 consecutive patients referred for computed tomography. Arch Med Sci (2015) 0.75
Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet (2008) 3.71
Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet (2004) 3.40
Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med (2005) 2.22
Functional class in patients with heart failure is associated with the development of diabetes. Am J Med (2003) 2.10
Efficacy of omega-3 fatty acid supplementation in primary and secondary prevention of coronary heart disease. Isr Med Assoc J (2004) 2.02
The metabolic syndrome entanglement: Cutting the Gordian knot. Cardiol J (2013) 2.01
Long-term changes in serum cholesterol level does not influence the progression of coronary calcification. Int J Cardiol (2010) 1.99
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol (2005) 1.61
Coronary calcium by spiral computed tomography predicts cardiovascular events in high-risk hypertensive patients. J Hypertens (2004) 1.57
Second-hand tobacco smoke in never smokers is a significant risk factor for coronary artery calcification. JACC Cardiovasc Imaging (2013) 1.52
Impact of the metabolic syndrome on the clinical outcomes of non-clinically diagnosed diabetic patients with acute coronary syndrome. Am J Cardiol (2007) 1.50
Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med (2006) 1.46
Calcification of the thoracic aorta as detected by spiral computed tomography among stable angina pectoris patients: association with cardiovascular events and death. Circulation (2008) 1.45
Exaggerated blood pressure response to exercise is not associated with masked hypertension in patients with high normal blood pressure levels. J Clin Hypertens (Greenwich) (2014) 1.43
Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation (2004) 1.42
The prevalence and anatomical patterns of intramuscular coronary arteries: a coronary computed tomography angiographic study. J Am Coll Cardiol (2007) 1.40
Pregnancy outcome following infections by coxsackie, echo, measles, mumps, hepatitis, polio and encephalitis viruses. Reprod Toxicol (2006) 1.38
Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? Cardiovasc Diabetol (2014) 1.31
Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction. Am J Cardiol (2006) 1.17
The ubiquitous interleukin-6: a time for reappraisal. Cardiovasc Diabetol (2010) 1.16
Ischemic preconditioning: nearly two decades of research. A comprehensive review. Atherosclerosis (2004) 1.15
Colchicine for the prevention of postpericardiotomy syndrome. Herz (2002) 1.13
Cognitive functions in severe congestive heart failure before and after an exercise training program. Int J Cardiol (2005) 1.12
Spiral computed tomography evidence of close correlation between coronary and thoracic aorta calcifications. Atherosclerosis (2004) 1.11
Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR). Cardiovasc Diabetol (2003) 1.10
Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol (2012) 1.10
Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J (2005) 1.09
Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol (2006) 1.09
Cardiovascular diabetology in the core of a novel interleukins classification: the bad, the good and the aloof. Cardiovasc Diabetol (2003) 1.09
"The metabolic syndrome... is dead": these reports are an exaggeration. Cardiovasc Diabetol (2011) 1.08
Current smoking, smoking cessation, and the risk of sudden cardiac death in patients with coronary artery disease. Arch Intern Med (2003) 1.07
Coronary calcification compared in patients with acute versus in those with chronic coronary events by using dual-sector spiral CT. Radiology (2003) 1.06
Admission blood glucose level and mortality among hospitalized nondiabetic patients with heart failure. Arch Intern Med (2006) 1.01
Coronary calcium in patients with and without diabetes: first manifestation of acute or chronic coronary events is characterized by different calcification patterns. Cardiovasc Diabetol (2013) 1.00
Insulin resistance is associated with increased risk of major cardiovascular events in patients with preexisting coronary artery disease. Am Heart J (2007) 0.99
Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Cardiovasc Diabetol (2012) 0.98
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovasc Diabetol (2006) 0.95
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovasc Diabetol (2009) 0.95
Macrovascular complications of metabolic syndrome: an early intervention is imperative. Int J Cardiol (2004) 0.93
Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data. PLoS One (2012) 0.93
Is hypoglycaemia a marker for increased long-term mortality risk in patients with coronary artery disease? An 8-year follow-up. Eur J Cardiovasc Prev Rehabil (2004) 0.93
Extra-cardiac findings on coronary computed tomography scanning. Isr Med Assoc J (2008) 0.92
Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes. Atherosclerosis (2006) 0.92
Accelerated coronary artery calcification in mildly reduced renal function of high-risk hypertensives: a 3-year prospective observation. J Hypertens (2003) 0.90
Optimal management of combined dyslipidemia: what have we behind statins monotherapy? Adv Cardiol (2008) 0.90
Biomarkers in cardiovascular diabetology: interleukins and matrixins. Adv Cardiol (2008) 0.89
Transcutaneous detection of aortic arch atheromas by suprasternal harmonic imaging. J Am Coll Cardiol (2002) 0.89
Oscillations in peripheral arterial tone in congestive heart failure patients: a new marker for Cheyne-Stokes breathing. Cardiology (2002) 0.89
"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study. Cardiovasc Diabetol (2010) 0.89
C-reactive protein as a predictor of incident ischemic stroke among patients with preexisting cardiovascular disease. Stroke (2006) 0.89
Increased prevalence of left ventricular hypertrophy in hypertensive women with type 2 diabetes mellitus. Cardiovasc Diabetol (2003) 0.88
Status of glucose metabolism in patients with heart failure secondary to coronary artery disease. Am J Cardiol (2002) 0.87
Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint. Herz (2004) 0.87
Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial). Am J Cardiol (2008) 0.87
Underuse of standard care and outcome of patients with acute myocardial infarction and chronic renal insufficiency. Cardiology (2006) 0.86
Calcification of the thoracic aorta by spiral computed tomography among hypertensive patients: associations and risk of ischemic cerebrovascular events. Int J Cardiol (2006) 0.86